Low-Impurity Sucrose Lowers Risk of Protein Instability in Biopharmaceutical Formulation
A new sucrose product from MilliporeSigma has reduced nanoparticle impurities.
MilliporeSigma developed a new filtration-based manufacturing process resulting in a new, highly purified sucrose grade with reduced levels of nanoparticle impurities (NPI). The new product, Sucrose EMPROVE EXPERT Ph Eur, ChP, JP, NF, is useful for biopharmaceutical formulation as a protein-stabilizing excipient. The product is part of the company’s Emprove Program, which facilitates drug product manufacturers’ risk assessment workflows and supplier qualification.
MilliporeSigma designed the new purification process and associated nanoparticle analytics of sucrose in a collaboration with Coriolis Pharma. Compared to non-purified sucrose, the new product offers a low level of NPIs on the limit of detection of current technologies, reducing risk of protein stability; less interference with analytical methods; high batch-to-batch consistency; and a reduced risk of API damage.
Source: MilliporeSigma
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development
March 26th 2024In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.
